

JUN 7 2005

TAFT, STETTINIUS & HOLLISTER LLP

425 WALNUT STREET, SUITE 1800
CINCINNATI, OHIO 45202-3957NORTHERN KENTUCKY OFFICE
SUITE 340
1717 DIXIE HIGHWAY
COVINGTON, KENTUCKY 41011-4704
859-381-2838
513-381-2838
FAX: 513-381-6613513-381-2838
FAX: 513-381-0205

www.taftlaw.com

COLUMBUS, OHIO OFFICE
21 EAST STATE STREET
COLUMBUS, OHIO 43215-4221
614-221-2838
FAX: 614-221-2007CLEVELAND OHIO OFFICE
3600 BP TOWER
200 PUBLIC SQUARE
CLEVELAND, OHIO 44114-2302
216-241-2838
FAX: 216-241-3707

FAX TRANSMISSION

From: Sharon Shelton
Paralegal

Date: June 7, 2005

Direct Line: 513-357-9406

To: USPTO
Attn: Examiner Montanari

Fax No. 703-872-9306

Confirmation No.

No. of Pages (including this cover page) four (4)

CONFIDENTIALITY NOTICE

This message may constitute privileged attorney-client communication or attorney work product, and unauthorized use or disclosure is prohibited. If you are not the intended recipient of this message, please advise us by calling collect at (513) 381-2838 and forward the document to us by mail at the address above.

If you do not receive all pages satisfactorily, please call (513) 381-2838, ext 173.
To send to any of our automatic machines, please dial direct: (513) 381-0205.

Message: DELIVER TO EXAMINER DAVID A. MONTANARI

Applicant : Robbins
Filed : July 3, 2003
Serial No. : 10/613,728
Title : A ROBUST INDUCIBLE CARDIAC PREFERRED EXPRESSION
SYSTEM FOR TRANSGENESIS
Docket No. : CHM02-GN053
Examiner : David A. Montanari
Art Unit : 1632

See attached Response to Election/Restriction Requirement in the above-referenced matter.

Sent By: _____ Time: _____

CMR: 70821

CONFIRMED BY FAX OPERATOR _____ TX/RX # _____

JUN 07 2005

Certificate of Transmission

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent and
Trademark Office, Fax No. (703) 872-9306 on:

6/7/2005
(Date)
(Sharon Shelton)PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Applicant : Robbins
Filed : July 3, 2003
Serial No. : 10/613,728
Title : A ROBUST INDUCIBLE CARDIAC PREFERRED
EXPRESSION SYSTEM FOR TRANSGENESIS
Docket No. : CHM02 GN053
Examiner : David A. Montanari
Art Unit : 1632

Hon. Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

This paper is filed in response to the Election/Restriction Requirement Office
action mailed on May 19, 2005 having a period of response extending through and
including June 19, 2005.

REMARKS

The May 19 Office action indicates that pending claims, 1-37, are subject to a
restriction or election requirement. The Office action indicates that Applicants are

{W0454720.1}

Serial No. 10/613,728
Election

Docket: CHM02-GN053

required under 35 U.S.C. §121 to elect a single disclosed species for prosecution on the merits.

As indicated on Pages 2-3 of the May 19 Office action, it is alleged that the application contains claims directed to six patentably distinct inventions:

Group I: Claims 1-15 drawn to an isolated nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1, an expression cassette, vector, and host cell comprising an isolated nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or said expression cassettes, vectors, or host cells comprising an isolated nucleic acid molecule having at least 95% identity with SEQ ID NO:1.

Group II: Claims 16-24, drawn to a transgenic animal, mouse, rabbit, dog, pig, goat, monkey, chimpanzee, or cow comprising a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or said transgenic animals comprising a nucleotide sequence that is at least 95% identical to SEQ ID NO:1.

Group III: Claims 22-28, and 37, drawn to a transgenic mouse comprising SEQ ID NO:5 or SEQ ID NO:6 or at having at least 95% identity to SEQ ID NO:5 or SEQ ID NO:6 operably linked to a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or having at least 95% identity to SEQ ID NO:1, and a method of identifying anti-cardiopathic compounds using said mouse.

Group IV: Claims 22-26, 29-30, and 37, drawn to a transgenic mouse comprising SEQ ID NO:7 or SEQ ID NO:8 or at having at least 95% identity to SEQ ID NO:7 or SEQ ID NO:8 operably linked to a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or having at least 95% identity to SEQ ID NO:1, and a method of identifying anti-cardiopathic compounds using said mouse.

Group V: Claims 22-28, and 31-36 drawn to a transgenic mouse comprising SEQ ID NO:5 or SEQ ID NO:6 or at having at least 95% identity to SEQ ID NO:5 or SEQ ID NO:6 operably linked to a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or having at least 95% identity to SEQ ID NO:1, and a method of altering expression of a nucleotide sequence of interest using said mouse.

Group VI: Claims 22-26, 29-36 drawn to drawn to a transgenic mouse comprising SEQ ID NO:7 or SEQ ID NO:8 or at having at least 95% identity to SEQ ID NO:7 or SEQ ID NO:8 operably linked to a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or

Serial No. 10/613,728
Election

Docket: CHM02-GN053


having at least 95% identity to SEQ ID NO:1, and a method of altering expression of a nucleotide sequence of interest using said mouse.

Applicant elects to prosecute the claims of Group I, without traverse.

If the Examiner holds that the instant election is proper, cancellation of claims 16-37 will follow the first Office action on the merits. Favorable consideration of the elected claims is respectfully requested.

If the Examiner wishes to discuss any aspect of this response, do not hesitate to contact the undersigned at the telephone number provided below.

Respectfully submitted,


Adelaide K. Leitzel
Reg. No. 51, 341

030074
Taft, Stettinius & Hollister LLP
425 Walnut Street; Suite 1800
Cincinnati, Ohio 45202-3957

Telephone: 513-357-9669
Fax: 513-381-0205
Email: leitzel@taftlaw.com